Disease Overview：Prostate Cancer（PCa）
Prostate cancer is a malignant neoplasm arising from the glandular epithelium of the prostate, predominantly affecting men over 50. It is often asymptomatic in early stages but may present with lower urinary tract symptoms, elevated serum prostate-specific antigen (PSA), or abnormal digital rectal examination findings. Diagnosis relies on multiparametric MRI, targeted transrectal ultrasound-guided biopsy, and histopathological confirmation with Gleason scoring. Risk stratification integrates clinical stage, PSA level, and tumor grade to guide management—ranging from active surveillance for low-risk disease to radical prostatectomy, external beam radiotherapy (including intensity-modulated and stereotactic techniques), brachytherapy, or systemic therapies (e.g., androgen deprivation therapy, novel hormonal agents, or PARP inhibitors) for intermediate- to high-risk or metastatic cases. Early detection significantly improves five-year overall survival, which exceeds 98% for localized disease.
China offers compelling advantages for international patients seeking prostate cancer care. Leading oncology centers—many accredited by JCI or ISO—employ multidisciplinary tumor boards and utilize cutting-edge technologies such as robotic-assisted laparoscopic prostatectomy (da Vinci Xi), MRI-guided radiotherapy (MR-Linac), and PSMA PET/CT for precise staging and treatment monitoring. Clinical outcomes align with global benchmarks: five-year biochemical recurrence-free survival after robotic surgery exceeds 90% for low- to intermediate-risk cohorts, supported by robust longitudinal data from institutions like Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or regulatory oversight by China’s National Medical Products Administration (NMPA). As a dedicated medical tourism agency, we facilitate seamless access to these resources—vetting hospitals, coordinating appointments with certified urologic oncologists, providing itemized, transparent pricing in advance, arranging visa support, translation, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.
Prostate Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Prostate Cancer (Oncology Department)
Non-Surgical / Conservative / Medication Options
*Indicated for low-risk localized disease, elderly patients, or those unfit for surgery.*
- •Active Surveillance (PSA ≤10 ng/mL, Gleason ≤6, clinical stage T1c–T2a):
- Annual multiparametric MRI (3.0T): $280–$350 - Confirmatory biopsy (12-core transrectal ultrasound-guided): $190–$240
- •Androgen Deprivation Therapy (ADT) (for intermediate/high-risk localized or metastatic disease):
- Oral anti-androgen (bicalutamide 50 mg/day): $35–$55/month - Baseline + quarterly labs (PSA, testosterone, LFTs, CBC): $75–$95/test panel
Surgical / Procedural / Interventional Options
*Eligibility: Clinical stage ≤T3a, PSA <20 ng/mL, Gleason ≤8, no distant metastasis, ECOG PS 0–1.*
- •Radical Prostatectomy (robot-assisted or open):
- Surgery fee (including robotic platform use if applicable): $4,200–$6,100 - Hospital stay (7–10 days, including pathology, catheter care, antibiotics): $1,800–$2,400
- •External Beam Radiotherapy (EBRT) (IMRT/VMAT, 38–42 fractions):
- Fractionated treatment (per course): $3,900–$5,300 - Weekly on-treatment labs (CBC, renal panel): $45–$60/session
Special / Complex Condition Options
- •Metastatic Castration-Resistant Prostate Cancer (mCRPC):
- Docetaxel chemotherapy (6-cycle regimen, including premedication, infusion, monitoring): $2,700–$3,500/cycle - Lu-177-PSMA therapy (2–4 cycles, includes radiopharmaceutical, dosimetry, hospitalization): $8,900–$11,600/cycle
- •High-Risk Localized Disease (T3b/T4 or Gleason 9–10):
Quick Selection Guide
- •Age <65, low comorbidity burden, localized disease: Radical prostatectomy ($6,400–$9,100) — optimal cure potential and long-term cost control.
- •Age ≥75 or significant cardiovascular/pulmonary comorbidities: Active surveillance ($510–$750/year) or ADT monotherapy ($155–$215/month) — avoids procedural risk.
- •Intermediate-risk, budget-constrained (<$5,000): IMRT radiotherapy ($4,220–$5,710) — high local control, outpatient delivery.
- •Metastatic or mCRPC: Lu-177-PSMA ($8,900–$11,600/cycle) for PSMA-positive disease; docetaxel ($2,700–$3,500/cycle) if PSMA-negative or rapid progression.
- •High-risk localized with limited financial capacity: Neoadjuvant ADT + EBRT ($5,100–$6,200) — avoids surgery costs while maintaining oncologic efficacy.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Prostate Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Prostate Cancer treatment with China top medical destinations:
